These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 26118499)

  • 1. Novel therapeutic strategies for multiple myeloma.
    Mimura N; Hideshima T; Anderson KC
    Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
    Kizaki M; Tabayashi T
    J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary drug therapies for multiple myeloma.
    de la Puente P; Azab AK
    Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
    Shay G; Hazlehurst L; Lynch CC
    J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.
    Podar K; Pecherstorfer M
    Expert Opin Pharmacother; 2017 Aug; 18(11):1061-1079. PubMed ID: 28604120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
    Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC
    Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma: signaling pathways and targeted therapy.
    Lu Q; Yang D; Li H; Niu T; Tong A
    Mol Biomed; 2024 Jul; 5(1):25. PubMed ID: 38961036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapeutic targets in multiple myeloma.
    Cottini F; Anderson K
    Clin Adv Hematol Oncol; 2015 Apr; 13(4):236-48. PubMed ID: 26352582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
    Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
    Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
    Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Insights in Anti-Angiogenesis in Multiple Myeloma.
    Ribatti D; Vacca A
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30002349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.
    Anreddy N; Hazlehurst LA
    J Cell Biochem; 2017 Jan; 118(1):15-25. PubMed ID: 27261328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel targeted therapies and combinations for the treatment of multiple myeloma.
    Agarwal A; Mahadevan D
    Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):2-15. PubMed ID: 22882073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple myeloma in the marrow: pathogenesis and treatments.
    Fairfield H; Falank C; Avery L; Reagan MR
    Ann N Y Acad Sci; 2016 Jan; 1364(1):32-51. PubMed ID: 27002787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
    Ria R; Vacca A
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances and practical use of monoclonal antibodies in multiple myeloma therapy.
    Lee HC; Weber DM
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):512-520. PubMed ID: 27913523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel targets and derived small molecule inhibitors in multiple myeloma.
    Podar K
    Curr Cancer Drug Targets; 2012 Sep; 12(7):797-813. PubMed ID: 22671928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Features of Multiple Myeloma.
    El Arfani C; De Veirman K; Maes K; De Bruyne E; Menu E
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.